HER2 Biomarkers
Breast Cancer Immunotherapy Response Markers Emerge From Single-Cell Sequencing Study
Researchers identified several pre-treatment markers that correlated with T-cell expansion and could be predictive of response to a PD1 inhibitor.
NICE Recommends Enhertu for Advanced HER2-Positive Breast Cancer Through Cancer Drugs Fund
While more data are collected, Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan is available to pretreated, HER2-positive breast cancer patients in the UK.
Keytruda, Hormone Therapy Combination Benefits Advanced Breast Cancer Subgroup in AACR Study
Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.
Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement
The company is studying gedatolisib with palbociclib and endocrine therapy in patients with ER-positive, HER2-negative metastatic breast cancer.